Nisha Pandey

Health and Me

IPF: Bristol Myers’ Experimental Drug Shows Promise Amid Limited Treatment Options

<span>Bristol Myers Squibb</span>’s experimental drug admilparant has shown promise in a late-stage clinical trial involving people with <span>idiopathic pulmonary fibrosis</span> (<span>IPF</span>), a progressive lung disease that causes irreversible scarring and gradually worsens breathlessness.

The pharmaceutical company announced on October 12 that the lower dose of the drug significantly slowed the decline in lung function compared to a placebo over 52 weeks. However, the higher dose did not meet the trial’s primary goal, raising questions about the treatment’s effects subject to dosage.

The Phase 3 ALOFT-IPF trial enrolled 1,255 patients and evaluated two doses of admilparant, 60 mg and 120 mg, taken twice daily. The study compared both doses with a placebo. Its primary goal was measuring changes in forced vital capacity (<span>FVC</span>) from the start of treatment to Week 52.

FVC measures the amount of air a person can forcefully exhale after taking a deep breath. A decline in this measure can indicate worsening lung function.

According to <a href="https://www.healthandme.com/health-news/india-caps-cancer-drug-trade-margins-patients-may-save-rs-2500-crore-article-156302820" data-type="tilCustomLink">Bristol Myers Squibb</a>, the 60 mg dose demonstrated a statistically significant benefit over placebo. The 120 mg dose also slowed the decline in lung function, but the difference did not reach statistical significance.

The company said the drug was generally well tolerated at both doses. Also, the treatment discontinuation due to adverse events remained low compared to placebo. Detailed trial results are yet to be presented.

<h2>What Is Idiopathic Pulmonary Fibrosis?</h2>

Also read: <a href="https://www.healthandme.com/health-wellness/can-delhis-air-pollution-increase-gi-cancer-risk-doctors-report-patients-as-young-as-15-article-156317450" data-type="tilCustomLink">Can Delhi’s Air Pollution Increase GI Cancer Risk? Doctors Report Patients As Young As 15</a>

IPF is a <a href="https://www.healthandme.com/health-news/sharmila-tagores-stage-zero-lung-cancer-can-surgery-prevent-progression-article-156313104" data-type="tilCustomLink">chronic lung disease</a> in which lung tissue becomes progressively scarred and stiff. As the scarring advances, the lungs become less efficient at transferring oxygen into the bloodstream, making everyday activities increasingly difficult.

The disease is described as idiopathic because its precise cause is unknown. Symptoms commonly include persistent breathlessness, a dry cough and fatigue. The condition can progress unpredictably, and the damage caused by fibrosis is generally irreversible.

Existing antifibrotic treatments can slow the loss of lung function, but they do not eliminate established scarring or cure the disease. This leaves a need for additional treatments that can delay progression.

Is AI Affecting Your Brain? Doctor on Cognitive Health, Parkinson’s & Dementia

Admilparant, also known as BMS-986278, is an oral drug designed to block the lysophosphatidic acid receptor 1 (LPA1).

The LPA1 signalling pathway is involved in processes linked to pulmonary fibrosis, including inflammation, tissue injury and the activation of cells that produce scar tissue. By blocking this receptor, admilparant is intended to interfere with mechanisms that contribute to the progression of lung scarring.

The drug is being investigated as a first-in-class treatment that uses this approach in people with IPF and <a href="https://www.healthandme.com/health-wellness/delhi-smog-can-you-really-tackle-pollution-season-with-an-n95-mask-and-air-purifier-article-156298593" data-type="tilCustomLink">progressive pulmonary fibrosis</a>.

“IPF remains one of the most complex and challenging lung diseases to treat, with unpredictable progression, irreversible scarring and a profound impact on patients’ daily lives,” said Fernando Martinez, chair of the ALOFT programme’s clinical steering committee and a professor of medicine at UMass Chan Medical School.

“These admilparant results represent an important advancement as there remains a need for therapies that are both effective and tolerable for patients living with IPF,” he added.

Bristol Myers Squibb said it would complete a comprehensive evaluation of the trial data and deal with regulatory authorities for submissions. The detailed findings are expected to be presented at a future meeting.

Health Conditions A-Z

health

ipf-bristol-myers-experimental-drug-shows-promise-amid-limited-treatment-options

bristol myers squibbs

bristol myers squibb

admilparant admilparant

bristol myers squibbs ipf drug

ipf drug

idiopathic pulmonary fibrosis

women-are-travelling-to-mexico-for-endometriosis-surgery-as-canada-is-doing-a-poor-job-at-providing-care

Women Are Travelling To Mexico For Endometriosis Surgery As Canada Is Doing A 'Poor' Job At Providing Care

sixth-measles-associated-death-reported-in-pennsylvania-as-cases-cross-1100

Sixth Measles-Associated Death Reported In Pennsylvania As Cases Cross 1,100

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Bristol Myers Squibb’s experimental drug admilparant has shown promise in a late-stage clinical trial involving people with idiopathic pulmonary fibrosis (IPF), a progressive lung disease that causes irreversible scarring and gradually worsens breathlessness.The pharmaceutical company announced on October 12 that the lower dose of the drug significantly slowed the decline in lung function compared to a placebo over 52 weeks. However, the higher dose did not meet the trial’s primary goal, raising questions about the treatment’s effects subject to dosage.The Phase 3 ALOFT-IPF trial enrolled 1,255 patients and evaluated two doses of admilparant, 60 mg and 120 mg, taken twice daily. The study compared both doses with a placebo. Its primary goal was measuring changes in forced vital capacity (FVC) from the start of treatment to Week 52.FVC measures the amount of air a person can forcefully exhale after taking a deep breath. A decline in this measure can indicate worsening lung function.According to Bristol Myers Squibb, the 60 mg dose demonstrated a statistically significant benefit over placebo. The 120 mg dose also slowed the decline in lung function, but the difference did not reach statistical significance.The company said the drug was generally well tolerated at both doses. Also, the treatment discontinuation due to adverse events remained low compared to placebo. Detailed trial results are yet to be presented.What Is Idiopathic Pulmonary Fibrosis?Also read: Can Delhi’s Air Pollution Increase GI Cancer Risk? Doctors Report Patients As Young As 15IPF is a chronic lung disease in which lung tissue becomes progressively scarred and stiff. As the scarring advances, the lungs become less efficient at transferring oxygen into the bloodstream, making everyday activities increasingly difficult.The disease is described as idiopathic because its precise cause is unknown. Symptoms commonly include persistent breathlessness, a dry cough and fatigue. The condition can progress unpredictably, and the damage caused by fibrosis is generally irreversible.Existing antifibrotic treatments can slow the loss of lung function, but they do not eliminate established scarring or cure the disease. This leaves a need for additional treatments that can delay progression.About Admilparant       Admilparant, also known as BMS-986278, is an oral drug designed to block the lysophosphatidic acid receptor 1 (LPA1).The LPA1 signalling pathway is involved in processes linked to pulmonary fibrosis, including inflammation, tissue injury and the activation of cells that produce scar tissue. By blocking this receptor, admilparant is intended to interfere with mechanisms that contribute to the progression of lung scarring.The drug is being investigated as a first-in-class treatment that uses this approach in people with IPF and progressive pulmonary fibrosis.“IPF remains one of the most complex and challenging lung diseases to treat, with unpredictable progression, irreversible scarring and a profound impact on patients’ daily lives,” said Fernando Martinez, chair of the ALOFT programme’s clinical steering committee and a professor of medicine at UMass Chan Medical School.“These admilparant results represent an important advancement as there remains a need for therapies that are both effective and tolerable for patients living with IPF,” he added.Bristol Myers Squibb said it would complete a comprehensive evaluation of the trial data and deal with regulatory authorities for submissions. The detailed findings are expected to be presented at a future meeting.

ipf: bristol myers’ experimental drug shows promise amid limited treatment options

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

IPF: Bristol Myers’ Experimental Drug Shows Promise Amid Limited Treatment Options

Sixth Measles-Associated Death Reported In Pennsylvania As Cases Cross 1,100

Mississippi Student Deaths Put Kratom Under Scrutiny: How Dangerous Is It?

Arthritis Day: Stanford Researchers Explore Possibility To Treat Osteoarthritis Without Knee Replacement Surgery

Health Conditions A-Z

Women Are Travelling To Mexico For Endometriosis Surgery As Canada Is Doing A 'Poor' Job At Providing Care

IPF: Bristol Myers’ Experimental Drug Shows Promise Amid Limited Treatment Options

Sixth Measles-Associated Death Reported In Pennsylvania As Cases Cross 1,100